1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Ireland >
  5. Alkermes Acquires Avadel Pharmaceuticals

M&A Deal Summary

Alkermes Acquires Avadel Pharmaceuticals

On October 22, 2025, Alkermes acquired life science company Avadel Pharmaceuticals for 2.1B USD

Acquisition Highlights
  • This is Alkermes’ 2nd transaction in the Life Science sector.
  • This is Alkermes’ largest (disclosed) transaction.
  • This is Alkermes’ 1st transaction in Ireland.

M&A Deal Summary
Date 2025-10-22
Target Avadel Pharmaceuticals
Sector Life Science
Buyer(s) Alkermes
Deal Type Add-on Acquisition
Deal Value 2.1B USD
Advisor(s) Morgan Stanley (Financial)
Goodwin Procter
Arthur Cox (Legal)

Target

Avadel Pharmaceuticals

Dublin, Ireland
Avadel Pharmaceuticals is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Its Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins. Avadel Pharmaceuticals was founded in 2015 and is based in Dublin, Ireland.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alkermes

Dublin, Ireland
Category Company
Founded 1987
Sector Life Science
Employees2,100
Revenue 1.6B USD (2024)
DESCRIPTION

Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for diseases that include schizophrenia, depression, addiction, multiple sclerosis, and cancer. Alkermes was founded in 1987 and is based in Dublin, Ireland.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Ireland M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-18 Rodin Therapeutics

Boston, Massachusetts, United States

Rodin Therapeutics, Inc. is a biopharmaceutical company discovering and developing first-in-class therapeutics by applying novel chemical strategies to target protein complexes that selectively modulate gene expression. Rodin Therapeutics is based in Boston, Massachusetts.

Buy $100M
Mergr

Solution for

Product

Company

Legal